Research map: Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

Back to the article

Papers in this map

  1. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial · Writing Group for the Women's Health Initiative Investigators · 2002 · 15966 citations · Cited by this paper
  2. Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision oncology · 2026 · Related
  3. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition · Nancy E. Avis · 2015 · 1022 citations · Cited by this paper
  4. Apoptosis-inducing potential of tilorone dihydrochloride in triple-negative breast cancer: in silico and in vitro evidences · 2026 · Related
  5. Longitudinal Analysis of the Association Between Vasomotor Symptoms and Race/Ethnicity Across the Menopausal Transition: Study of Women’s Health Across the Nation · Ellen B. Gold · 2006 · 937 citations · Cited by this paper
  6. EPA-loaded silica nanoemulsions attenuate DEN-induced hepatic fibroinflammation by modulating homocysteine, PKCα/NF-κB, and Nrf2 signaling · 2026 · Related
  7. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study · Naga Chalasani · 2015 · 923 citations · Cited by this paper
  8. Cycloastragenol overcomes trastuzumab resistance in HER2-positive breast cancer by regulating cell cycle and epithelial-mesenchymal transition through EZH2/PTEN/AKT pathway · 2026 · Related
  9. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline · Cynthia A. Stuenkel · 2015 · 881 citations · Cited by this paper
  10. Exploring betanin regulatory impact on TGF-β and PI3K/AKT pathways in oral cancer · 2026 · Related
  11. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes · Naomi E. Rance · 2013 · 379 citations · Cited by this paper
  12. Myrtenol modulates TWEAK/TLR4–NF-κB, miR-21, PTEN, and ERK-1 expressions and improves behavioral outcomes in a rat glioblastoma model · 2026 · Related
  13. Menopause transition: Physiology and symptoms · Vikram Sinai Talaulikar · 2022 · 330 citations · Cited by this paper
  14. Protective effects of ginseng against reproductive injury: mechanisms and research progress · 2026 · Related
  15. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes · Jennifer Whiteley · 2013 · 327 citations · Cited by this paper
  16. Development of citrinin-loaded liposomes and in vitro toxicogenetic evaluation on breast cells · 2026 · Related
  17. A curated and standardized adverse drug event resource to accelerate drug safety research · Juan M. Banda · 2016 · 260 citations · Cited by this paper
  18. Luteolin alleviates inflammation by inhibiting the PI3K-Akt-FOXO3a pathway · 2026 · Related
  19. Acetaminophen Hepatotoxicity: Paradigm for Understanding Mechanisms of Drug-Induced Liver Injury · Hartmut Jaeschke · 2024 · 245 citations · Cited by this paper
  20. Novel copper–phenothiazine–amino acid complexes exhibit selective anticancer activity via induction of apoptosis and cell cycle arrest in HepG2 cells · 2026 · Related
  21. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS) · Roger J. Yu · 2020 · 227 citations · Cited by this paper
  22. Osimertinib-Induced Cardiotoxicity · Kartik Anand · 2019 · 207 citations · Cited by this paper
  23. A Neural Circuit Underlying the Generation of Hot Flushes · Stéphanie L. Padilla · 2018 · 169 citations · Cited by this paper
  24. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN · Rebecca C. Thurston · 2021 · 169 citations · Cited by this paper
  25. Revised global consensus statement on menopausal hormone therapy · T. J. de Villiers · 2016 · 164 citations · Cited by this paper
  26. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice · Andrea Ricardo Genazzani · 2021 · 95 citations · Cited by this paper
  27. Fezolinetant in the treatment of vasomotor symptoms associated with menopause · Herman T. Depypere · 2021 · 92 citations · Cited by this paper
  28. Mechanisms of drug induced liver injury · Josephine Skat‐Rørdam · 2025 · 50 citations · Cited by this paper
  29. Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis · Aunchalee Jaroenlapnopparat · 2023 · 46 citations · Cited by this paper
  30. Tacr3/NK3R: Beyond Their Roles in Reproduction · Wenwen Zhang · 2020 · 36 citations · Cited by this paper
  31. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial · Katrin Schaudig · 2024 · 35 citations · Cited by this paper
  32. The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders · Nick Pantaleo · 2010 · 34 citations · Cited by this paper
  33. Fezolinetant: First Approval · Arnold Lee · 2023 · 34 citations · Cited by this paper
  34. Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs · Ayako M. Suzuki · 2024 · 33 citations · Cited by this paper
  35. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative · Eric B. Cohen · 2024 · 27 citations · Cited by this paper
  36. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor · Yunyan Pan · 2024 · 24 citations · Cited by this paper
  37. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS) · Shupeng Zou · 2023 · 23 citations · Cited by this paper
  38. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2) · Rossella Elena Nappi · 2024 · 18 citations · Cited by this paper
  39. Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy · Marla Shapiro C M · 2024 · 18 citations · Cited by this paper

Source: OpenAlex (CC0)